Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 727.20M | 844.60M | 1.46B | 1.39B | 808.70M |
| Total Depreciation and Amortization | 123.20M | 145.00M | 136.70M | 135.10M | 126.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 192.00M | 175.20M | -603.00M | -154.40M | -20.10M |
| Change in Net Operating Assets | 36.50M | 5.90M | 625.00M | -227.90M | 129.60M |
| Cash from Operations | 1.08B | 1.17B | 1.62B | 1.14B | 1.05B |
| Capital Expenditure | -230.60M | -248.70M | -201.40M | -219.00M | -229.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -300.00K | -3.00M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.30M | 469.30M | -198.50M | -875.00M | 876.80M |
| Cash from Investing | -428.90M | 220.30M | -402.90M | -1.09B | 647.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 163.10M | 503.50M | 40.30M | 31.50M | 60.60M |
| Repurchase of Common Stock | -867.50M | -1.19B | -667.00M | -1.07B | -1.05B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -97.80M | -92.70M | -91.20M | -92.60M | -93.80M |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -10.30M |
| Cash from Financing | -802.20M | -780.10M | -717.90M | -1.13B | -1.09B |
| Foreign Exchange rate Adjustments | -900.00K | -300.00K | -400.00K | 400.00K | 600.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -153.10M | 610.60M | 497.50M | -1.08B | 604.00M |